首页> 美国卫生研究院文献>Journal of Lipid Research >In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling
【2h】

In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling

机译:人皮肤组织中葡萄糖脑苷脂酶的原位可视化:酶谱与基于活性的探针标记

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epidermal β-glucocerebrosidase (GBA1), an acid β-glucosidase normally located in lysosomes, converts (glucosyl)ceramides into ceramides, which is crucial to generate an optimal barrier function of the outermost skin layer, the stratum corneum (SC). Here we report on two developed in situ methods to localize active GBA in human epidermis: i) an optimized zymography method that is less labor intensive and visualizes enzymatic activity with higher resolution than currently reported methods using either substrate 4-methylumbelliferyl-β-D-glucopyranoside or resorufin-β-D-glucopyranoside; and ii) a novel technique to visualize active GBA1 molecules by their specific labeling with a fluorescent activity-based probe (ABP), MDW941. The latter method pro­ved to be more robust and sensitive, provided higher resolution microscopic images, and was less prone to sample preparation effects. Moreover, in contrast to the zymography substrates that react with various β-glucosidases, MDW941 specifically labeled GBA1. We demonstrate that active GBA1 in the epidermis is primarily located in the extracellular lipid matrix at the interface of the viable epidermis and the lower layers of the SC. With ABP-labeling, we observed reduced GBA1 activity in 3D-cultured skin models when supplemented with the reversible inhibitor, isofagomine, irrespective of GBA expression. This inhibition affected the SC ceramide composition: MS analysis revealed an inhibitor-dependent increase in the glucosylceramide:ceramide ratio.
机译:表皮β-葡萄糖脑苷脂酶(GBA1)是一种通常位于溶酶体内的酸性β-葡萄糖苷酶,可将(葡萄糖基)神经酰胺转化为神经酰胺,这对于产生最外层皮肤角质层(SC)的最佳屏障功能至关重要。在这里,我们报告了两种在人的表皮中定位活性GBA的原位开发方法:i)一种优化的酶谱分析方法,与目前报道的使用底物4-甲基伞形基-β-D-的方法相比,该方法耗费的劳动强度较小,并且具有较高的分辨率可视化酶活性。吡喃葡萄糖苷或试卤灵-β-D-吡喃葡萄糖苷; ii)一种新颖的技术,可以通过基于荧光活性的探针(ABP)MDW941对其进行特异性标记来可视化活性GBA1分子。后一种方法被证明具有更高的鲁棒性和灵敏度,可提供更高分辨率的显微图像,并且不易受到样品制备的影响。此外,与可与各种β-葡萄糖苷酶反应的酶学底物相反,MDW941特别标记了GBA1。我们证明表皮中的活性GBA1主要位于活表皮和SC的较低层的界面处的细胞外脂质基质中。通过ABP标记,我们观察到在补充3D培养的皮肤模型中GBA1活性降低时,无论其是否表达GBA,均可添加可逆抑制剂异黄明。这种抑制作用影响了SC神经酰胺的组成:MS分析表明,糖基神经酰胺:神经酰胺比率呈抑制剂依赖性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号